|
gptkbp:instanceOf
|
gptkb:antibiotic
gptkb:drug
|
|
gptkbp:approvalYear
|
2019
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
J01DI04
|
|
gptkbp:brand
|
gptkb:Fetroja
|
|
gptkbp:CASNumber
|
1225205-84-9
|
|
gptkbp:chemicalFormula
|
C30H34N8O10S2
|
|
gptkbp:countryOfOperation
|
gptkb:European_Union
gptkb:United_States
|
|
gptkbp:developedBy
|
gptkb:Shionogi_&_Co.
|
|
gptkbp:eliminationHalfLife
|
2-3 hours
|
|
gptkbp:excretion
|
renal
|
|
gptkbp:genericName
|
cefiderocol
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Fetroja
|
|
gptkbp:indication
|
complicated urinary tract infections
hospital-acquired bacterial pneumonia
ventilator-associated bacterial pneumonia
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
siderophore cephalosporin
|
|
gptkbp:metabolism
|
minimal
|
|
gptkbp:notEffectiveAgainst
|
Gram-positive bacteria
anaerobic bacteria
|
|
gptkbp:pregnancyCategory
|
unknown
|
|
gptkbp:proteinBinding
|
40-60%
|
|
gptkbp:routeOfAdministration
|
intravenous
|
|
gptkbp:sideEffect
|
nausea
vomiting
diarrhea
constipation
infusion site reactions
|
|
gptkbp:spectrumOfActivity
|
Gram-negative bacteria
|
|
gptkbp:bfsParent
|
gptkb:Shionogi
|
|
gptkbp:bfsLayer
|
6
|